Investigated for use/treatment in constipation, ileus, and pediatric indications.
Mode of Action:
Prucalopride (PRU) is a selective high affinity 5-HT4 agonist, which are involved in initiating peristalsis. Prucalopride alters colonic motility patterns via serotonin 5-HT4 receptor stimulation: it stimulates colonic mass movements, which provide the main propulsive force for defecation.
In vitro, human liver metabolism is very slow and only minor amounts of metabolites are found.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs